Seragon and MaxScientific collaborate to enhance NAD+ optimization and bioavailability of longevity supplements.
Two longevity focused biotech companies have teamed up on the development of nutraceuticals aimed at aging and longevity intervention. Irvine, California-based MaxScientific has announced a licensing agreement with Seragon Biosciences to redefine the formulation of its nutraceutical products for healthy aging.
A primary focus of the partnership is on the optimization of cellular NAD+ levels. The new formulation will integrate Seragon’s proprietary “NAD-boosting technology” with the goal of enhancing metabolic and mitochondrial function. The details of the technology were not disclosed, although the companies did reveal it will replace NAD precursor nicotinamide mononucleotide (NMN), which was part of the original formulation.
MaxScientific says it also plans to integrate pharmaceutical delivery technologies developed by Seragon, which are designed to improve the bioavailability and cellular absorption of its product’s active ingredients.
A spokesperson for MaxScientific said that the partnership aimed to set “a new standard for interventions targeting critical biological mechanisms implicated in cellular aging.”
Earlier this year, Seragon announced positive preclinical study results for an “anti-aging candidate”, claiming that its 300-mouse study demonstrated “one of the largest extensions of lifespan and healthspan to date” in treated animals. The company said that mice treated in the study had increased expression of longevity-associated genes and reduced expression of aging-related genes, alongside “beneficial changes” in biomarkers associated with a younger biological age, enhanced endurance and reduced frailty scores compared with controls.
